PMID- 27738572
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 8
IP  - 9
DP  - 2016 Sep 9
TI  - Infliximab-Associated Psoriasiform Dermatitis: Case Report and Review of a 
      Seemingly Paradoxical Inflammatory Response.
PG  - e773
LID - e773
AB  - BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) inhibitors, such as infliximab, 
      adalimumab, and certolizumab pegol are effective agents in the treatment of 
      inflammatory bowel disease. Some individuals undergoing anti-TNF-alpha therapy for 
      Crohn's disease or ulcerative colitis develop psoriasiform lesions. This is a 
      paradoxical finding, as classical psoriasis is known to respond to these agents. 
      PURPOSE: The clinical features of anti-TNF-alpha-induced psoriatic dermatitis are 
      described. METHOD: A 60-year-old man with Crohn's disease treated with 
      infliximab, who developed anti-TNF-alpha-induced psoriasiform dermatitis, is 
      described. RESULTS: The man developed erythematous skin lesions in the bilateral 
      axillae two years after beginning infliximab treatment for Crohn's disease. 
      Biopsy revealed psoriasiform dermatitis, consistent with a diagnosis of 
      anti-TNF-alpha-induced psoriasiform dermatitis. He was treated with clobetasol 0.05% 
      ointment twice daily for two weeks and had significant improvement. Subsequently, 
      he used the corticosteroid ointment two days per week and calcipotriene 0.005% 
      ointment twice daily for five days per week to achieve and maintain clear skin. 
      CONCLUSIONS: Anti-TNF-alpha-induced psoriasiform dermatitis is an infrequent 
      complication of infliximab therapy. However, the condition may require 
      discontinuation of the anti-TNF-alpha agent. Anti-TNF-alpha-induced psoriasiform 
      dermatitis should be considered in the differential diagnosis when evaluating a 
      new erythematous skin condition in an individual with a history of inflammatory 
      bowel disease who is being treated with a TNF-alpha inhibitor.
FAU - Loh, Tiffany Y
AU  - Loh TY
AD  - School of Medicine, University of California, San Diego.
FAU - Cohen, Philip R
AU  - Cohen PR
AD  - Department of Dermatology, University of California, San Diego.
LA  - eng
PT  - Case Reports
DEP - 20160909
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC5059146
OTO - NOTNLM
OT  - bowel
OT  - crohn's
OT  - dermatitis
OT  - inflammatory
OT  - infliximab
OT  - interferon
OT  - psoriasiform
OT  - spongiotic
OT  - tumor necrosis factor
OT  - ulcerative colitis
COIS- The authors have declared that no competing interests exist.
EDAT- 2016/10/16 06:00
MHDA- 2016/10/16 06:01
PMCR- 2016/09/09
CRDT- 2016/10/15 06:00
PHST- 2016/10/15 06:00 [entrez]
PHST- 2016/10/16 06:00 [pubmed]
PHST- 2016/10/16 06:01 [medline]
PHST- 2016/09/09 00:00 [pmc-release]
AID - 10.7759/cureus.773 [doi]
PST - epublish
SO  - Cureus. 2016 Sep 9;8(9):e773. doi: 10.7759/cureus.773.